je.st
news
Amgen says Kyprolis doubles progression-free survival vs Velcade
2015-03-02 04:09:37| Biotech - Topix.net
Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday. REUTERS: Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.
Tags: survival
doubles
amgen
progressionfree survival
Category:Biotechnology and Pharmaceuticals